MYCL1/L-Myc Antibody

Western blot shows nuclear extracts of HeLa human cervical epithelial carcinoma cell line, A549 human lung carcinoma cell line, JEG-3 human epithelial choriocarcinoma cell line, and NIH-3T3 mouse embryonic fibroblast cell line. PVDF membrane was probed with 1 µg/mL of Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for MYCL1/L-Myc at approximately 40 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2.

MYCL1/L-Myc was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Goat Anti-Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red, upper panel; Catalog # NL001) and counterstained with DAPI (blue, blue panel). Specific staining was localized to cytoplasm and nuclei. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

MYCL1/L-Myc was detected in immersion fixed NIH3T3 mouse embryonic fibroblast cell line using Goat Anti-Human/Mouse MYCL1/L-Myc Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4050) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the Northern-Lights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red, upper panel; Catalog # NL001) and counterstained with DAPI (blue, lower panel). Specific staining was localized to cytoplasm and nuclei. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Differential effects of MYC and NF-kappa B on glycolytic gene and MCT1 levels.A) Promoter region of MCT1 includes MYC and NF-kappa B binding sites. Shading reflects four independent IMR90 DNase I hypersensitivity datasets. B) IMR90 cells stably expressing ST, GFP or p53DD + hTERT (PH) and MCPyV tumor-derived early-region (PHE) with inducible expression of MYC, MYCN or MYCL were treated with dox (+) for 48 hours. Lysates were immunoblotted with the indicated antibodies. C) IMR90 PH and PHE cells inducibly expressing MYC or MYCL were transfected with RelA-specific pooled siRNA (siRelA) or non-targeting siRNA (siCtrl). After 24 hours, cells were refed with dox containing media and lysed after an additional 48 hours. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.

Differential effects of MYC and NF-kappa B on glycolytic gene and MCT1 levels.A) Promoter region of MCT1 includes MYC and NF-kappa B binding sites. Shading reflects four independent IMR90 DNase I hypersensitivity datasets. B) IMR90 cells stably expressing ST, GFP or p53DD + hTERT (PH) and MCPyV tumor-derived early-region (PHE) with inducible expression of MYC, MYCN or MYCL were treated with dox (+) for 48 hours. Lysates were immunoblotted with the indicated antibodies. C) IMR90 PH and PHE cells inducibly expressing MYC or MYCL were transfected with RelA-specific pooled siRNA (siRelA) or non-targeting siRNA (siCtrl). After 24 hours, cells were refed with dox containing media and lysed after an additional 48 hours. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.

MYC isoforms differentially regulate glycolysis gene expression and ECAR of MCC cells.A) MKL-1 and WaGa cells containing inducible vectors for MYC, MYCN or MYCL were treated with (+) or without (-) dox for 72 hours and lysates were immunoblotted with the indicated antibodies. B) ECAR (mpH/min) of MKL-1 cells inducibly expressing GFP, MYC, MYCN or MYCL after 72 hours of dox addition (minutes). Cells were treated with oligomycin (1 μM) at the indicated time point. *P < 0.05 calculated using unpaired student’s T test between MYC and MYCL samples. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.ppat.1006020), licensed under a CC-BY license. Not internally tested by R&D Systems.

Product Discontinued

MYCL1/L-Myc Antibody Summary

• Immunogen: E. coli-derived recombinant human MYCL1/L‑Myc
  Gly16-Asn139
  Accession # P12524
• Specificity: Detects human and mouse MYCL1/L‑Myc in Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: MYCL1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 5-15 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MYCL1/L-Myc Antibody

• BHLHE38
• bHLHe38myc-related gene from lung cancer
• Class E basic helix-loop-helix protein 38
• LMyc
• L-Myc
• LMYCl-myc-1 proto-oncogene
• MYCL
• MYCL1
• protein L-Myc-1
• v-myc avian myelocytomatosis viral oncogene homolog 1, lung carcinoma derived
• v-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian)

Background

MYCL1 is a member of the MYC family that was isolated from small cell lung carcinoma. Like the other members of the MYC family, MYCL1 is a proto-oncogene transcription factor belonging to the helix-loop-helix basic leucine zipper (HLH bzip) family. With its heterodimeric partners, MYCL1 binds to the DNA consensus site 5’ CACGTG 3’. MYCL1 is implicated in controlling a wide range of cellular processes from cellular proliferation to apoptosis.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MYCL1/L-Myc Antibody (AF4050)(2)

Publications using AF4050

• X Gong, J Du, SH Parsons, FF Merzoug, Y Webster, PW Iversen, LC Chio, RD Van Horn, X Lin, W Blosser, B Han, S Jin, S Yao, H Bian, C Ficklin, L Fan, A Kapoor, S Antonysamy, AM Mc Nulty, K Froning, D Manglicmot, A Pustilnik, K Weichert, SR Wasserman, M Dowless, C Marugán, C Baquero, MJ Lallena, SW Eastman, YH Hui, MZ Dieter, T Doman, S Chu, HR Qian, XS Ye, DA Barda, GD Plowman, C Reinhard, RM Campbell, JR Henry, SG Buchanan Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene Cancer Discov, 2018-10-29;0(0):. 2018-10-29 [PMID: 30373917] (Western Blot, Human)
• Merkel Cell Polyomavirus Small T Antigen Promotes Pro-Glycolytic Metabolic Perturbations Required for Transformation PLoS Pathog., 2016-11-23;12(11):e1006020. 2016-11-23 [PMID: 27880818] (Western Blot, Human)

Review for MYCL1/L-Myc Antibody (AF4050) (1)

Average Rating: 3

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer WB Human 12/18/2018

Summary

• Application: Western Blot
• Sample Tested: small cell lung cancer cells
• Species: Human
• Lot: YIH021810B

Comments

• Comments: ripa lysis
  30ug protein loaded.
  
  Not sure which band or is it the right band

Bioinformatics

• Gene Symbol: MYCL1
• Uniprot:
  • P12524()